Contact Us
Language
English 日本語

Leading life sciences IP experts

Technical and legal capabilities accurately matched to your needs

Intellectual property is a critical asset in the life sciences sector. With Marks & Clerk, you work with leading life science experts, whose technical and legal capabilities are accurately matched to your needs. People who understand your world and are experienced in identifying, protecting, enforcing and maximising the value of IP rights for life sciences businesses.

Technical and sector expertise

Marks & Clerk has a large team of leading life science experts. The size of our team means that we have extensive expertise in all life science technical areas, including small molecules, biologics, molecular biology, gene therapy, virology, plant biotechnology, vaccines, wounds, immunology, bioinformatics and diagnostic methods. 

We also have expertise in all other exclusivities particular to the life sciences sector, including:

  • supplementary protection certificates (SPCs) for medicinal and plant protection products
  • patent term extensions
  • regulatory exclusivities
  • plant variety rights.

Specialists

for the result you need

Photo: Monique Chu

Monique Chu

Partner Chinese and Chartered (UK) Patent Attorney
Monique has notable experience in biotechnology, pharmaceutical, cosmetic related and mechanical inventions.
Photo: James Baker

James Baker

Partner Canadian Patent Agent
James Baker is a partner and registered Canadian patent agent in the Ottawa office of Marks & Clerk Canada.

Upasana Patel

Partner Registered (SG) and Chartered (UK) Patent Attorney
Upasana qualified as a Singapore Registered Patent Attorney in 2007 and as a Chartered (UK) Patent Attorney in 2012.

Will Nieuwenhuys

Partner Chartered (UK) and European Patent Attorney
Will has experience in a variety of technical fields, with particular expertise in small molecule organic and pharmaceutical chemistry.

Integrated team

We work collaboratively across different disciplines to achieve the best possible outcome

Our team includes patent attorneys, trade mark attorneys, commercial lawyers and IP litigators. This combined expertise and experience means that we can provide every type of intellectual property service you need from the moment an invention is identified through to enforcement or defence of IP rights in opposition proceedings or litigation. We’re used to working collaboratively across different disciplines to achieve the best possible outcomes for our clients.

As well as identifying, enforcing and defending IP rights, we carry out life science due diligence projects and commercial work, including when preparing for investment and IPOs.

Our team acts in high value disputes before the courts and patent offices, often in coordinated, multi-jurisdictional proceedings.

Clients

Our life sciences team acts for world-leading multinationals as well as start-ups, universities, public sector organisations, and established SMEs. Our clients include businesses from the pharmaceutical, biotechnology, food technology and agritech sectors.

“The group stands out for its particularly busy Patent Cooperation Treaty (PCT) patent filing practice and its longstanding experience in matters at the intersection of litigation and prosecution, making the team a popular choice for sophisticated matters, especially for pharmaceutical and biopharmaceutical companies.”
The Legal 500, 2020

“Pharmaceutical multinationals flock to the firm with cross-jurisdictional litigation and transactions instructions, alongside routine filing and prosecution tasks”
IAM Patent 1000, 2020

Latest Insights

Insight
- 19 January 2022

The Unified Patent Court comes back to life

The long-awaited Unified Patent Court (the UPC), which will provide a new forum for patent litigation in 24 EU countries, is finally getting ready to open its doors.
Read more
Insight
- 02 December 2021

M&C Reacts: EPO stays examination and oppositions where “plausibility” is in issue

The question of whether evidence filed after the priority date of a patent application (so-called “post-published evidence”) can be taken into account in the determination of inventive step has been a hot topic in Europe for several years.
Read more
Insight
- 03 November 2021

M&C Reacts: Neurim v Mylan: A Most Unusual Case - Take Two Part Two

In a further preliminary skirmish in the Neurim v Mylan battle, the Patents Court has granted Neurim’s wish to have its day in court. Mylan (now Viatris) failed in its bid to stay the UK proceedings pending determination of the EPO opposition proceedings.
Read more

Stay informed

IP insights direct to your inbox

Subscribe